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post-hemodialysis target blood pressure7 may therefore
paradoxically decrease life expectancy rather than prolong
it.
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To the Editor: Hallelujah! The long anticipated results of the
Dialysis Clinical Outcomes Revisited (DCOR) trial are finally
published.1 To our surprise, despite triumphant press releases
and hyperbolic pronouncements made in industry-sponsored
symposia at nephrology meetings 2 years ago, the DCOR
study actually found no mortality benefit among hemodia-
lysis patients treated with sevelamer as compared with
patients treated with CCPBs (calcium-containing phosphate
binders). At once, the NKF-KDOQI/KDIGO opinion-based
recommendations regarding the possible advantages of the
non-calcium, non-aluminum resin-based phosphate binder,
sevelamer become moot. In these guidelines, the postulated
rationale for preferential use of non-calcium binders in
certain clinical circumstances was based on observational
studies showing an association between the use of CCPB
and mortality risk or intervention trials employing surrogate
end points such as cardiovascular calcification.2,3 These
important results from DCOR imply that clinicians can now
confidently prescribe effective and substantially less expensive
CCPB therapy unburdened by prior expert ‘opinion’
suggesting that CCPBs represent arcane and potentially
cardiotoxic therapy. Case closed, right? Well probably not.
Although statistically invalid given the negative results for the
primary outcomes (all-cause and cardiovascular mortality),
the authors conducted a post hoc analysis to study the effect
of patient age on the results. A major case is made for a
possible benefit on all-cause mortality in subjects aged over
65 years treated with sevelamer. This post hoc analysis will
undoubtedly become fodder for pharmaceutical company
marketing and quite possibly will be used to justify additional
opinion-based recommendations for preferential use of
sevelamer in the older dialysis patient population. However,
we are quite concerned about incomplete reporting of the
results of the DCOR study. The reported dropout rate (49%)
is extremely high and unacceptable given the simplicity of the
DCOR study design. DCOR is a mortality study that enrolled
only Medicare-eligible dialysis patients. Although study
subjects may withdraw consent for participation, an intent-
to-treat analysis of all enrolled subjects is feasible, as there
are only three possible outcomes regarding mortality (alive
on dialysis, alive after kidney transplant, or dead). Although
data are not reported, the authors mention that an intent-
to-treat analysis of all-cause mortality employing the Centers
for Medicare and Medicaid Services (CMS) database also
showed no difference in all-cause mortality. Did the
postulated age-related difference in mortality persist in this
intent-to-treat data set? Full reporting of intent-to-treat data
analysis should have been a prerequisite for publication and
remains mandatory for any meaningful analysis of DCOR
results.
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The case against calcium-based binders has been accumu-
lating for years.1 The presence, and extent, of vascular
calcifications are strong predictors of cardiovascular and
all-cause mortality.2,3 The dose of calcium-based phosphate
binders (acetate or carbonate) has been linked to the
severity of vascular calcification.2,4 As a result of these
observations, the US National Kidney Foundation had
issued guidelines calling for lower serum phosphorus and
calcium targets in dialysis patients, limitation of the dose
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of calcium used in phosphate-binding agents, and avoid-
ance of calcium altogether in patients with hypercalcemia,
overly suppressed intact parathyroid hormone, or with
severe arterial or other soft tissue calcification.5,6 Since the
guidelines’ publication cut-off date (2002), more data have
emerged against calcium, including a direct link between
the use of calcium-based binders and increase in calcifica-
tion,7,8 although not the dose of calcium in one of the
studies.8 Now two outcome studies (Renagel In New
Dialysis Patients (RIND) and Dialysis Clinical Outcomes
Revisited (DCOR)) showing that intake of calcium-based
binders impacts patient mortality (incident and elderly
patient populations, respectively), have been published.
These represent the first and only prospective randomized
studies ever to show a decline in mortality in hemodialysis
patients brought about by a therapeutic maneuver.
Doctors Nolan and McCarron state that the DCOR
‘authors conducted a post hoc analysis to study the effect of
patient age on the results’.9 I note that patients X65 years of
age, who had a superior survival when treated with
sevelamer, did so as the result of a pre-specified analysis in
which a significant treatment-by-age interaction was required
as a gating criteria before making inferences about age-
stratified results. While the older age group had more than
twice the mortality rate of the younger group, allowing better
precision in estimating treatment effect, there are several
reasons why sevelamer might be expected to have a greater
impact in this population. In nearly all publications
concerning vascular calcification, age is an independent
predictor of baseline calcification severity.2–4,8,10–12 Further-
more, patients with more severe calcification have the
greatest increase in calcification over time.7,8 In another
recent study, Doctors Nolan and McCarron ignore the
coronary calcification scores at the time of initiation of
dialysis, and the choice of phosphate binder, which were
found to be strong independent predictors of mortality. In
that same trial, which was an extension of the RIND trial,
patients previously assigned to sevelamer demonstrated a
significant survival benefit relative to those assigned to
calcium-based phosphate binders.13 Since these robustness
assessments were confirmatory, the finding corroborates the
body of knowledge that is accruing regarding progression of
coronary calcification in an aging hemodialysis population,
and the associated mortality risk is so high, it was deemed an
important finding to communicate to the clinical community.
The intent-to-treat analysis Doctors Nolan and
McCarron insist upon employs an entirely different data
source from that of the DCOR study, namely the Centers
for Medicare and Medicaid database. This analysis was
conducted by investigators independent from those of the
DCOR study, and will be reported by them separately.
In conclusion, it is not a matter which treatment is cheaper,
but which treatment is better for our patients’ survival. The
evidence speaks for itself; calcium is clearly linked to poor
outcomes in our patients while sevelamer is the only
phosphate binder with two prospective outcomes studies that
have demonstrated a significant survival benefit in incident
dialysis patients and in elderly prevalent dialysis patients.
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To the Editor: The paper1 raised the possibility that distal
renal tubular acidosis (dRTA) induces interstitial changes
without stone formation by unknown mechanisms. Since
proton secretion is coupled with bicarbonate secretion in
type A intercalated cells (A-IC), bicarbonate secretion into
the interstitial space should also be impaired in dRTA. In
other types of acidosis, this bicarbonate secretion is
stimulated, and the acidosis around the collecting ducts is
corrected. In dRTA, the decreased bicarbonate secretion
worsens the acidosis around the collecting duct. Since low pH
induces a variety of responses in cells, unphysiologically low
pH may cause interstitial fibrosis in dRTA.
Since the thick ascending limbs of Henle (TALHs) are
located near the collecting ducts, the TALHs are also exposed
to very low pH in dRTA. The microperfusion study indicated
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